Int J Angiol 2017; 26(04): 267-270
DOI: 10.1055/s-0037-1604333
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Precipitous Resolution of Type-A Intramural Hematoma with Medical Management in a Patient with Metastatic Stage 4 Renal Cell Carcinoma

Authors

  • Camilo A. Velasquez

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
  • Syed Usman Bin Mahmood

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
  • Mohammad A. Zafar

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
  • Adam J. Brownstein

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
  • Ayman Saeyeldin

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
  • Bulat A. Ziganshin

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
    2   Department of Surgical Diseases 2, Kazan State Medical University, Kazan, Russia
  • John A. Elefteriades

    1   Aortic Institute at Yale New Haven Hospital, Yale University School of Medicine, New Haven, Connecticut
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. August 2017 (online)

Preview

Abstract

Intramural hematoma (IMH) is a variant form of aortic dissection characterized by involvement of the aortic media without the presence of an overt intimal flap. Surgical extirpation is the standard of care for type-A IMH in the Western world. However, a conservative approach with anti-impulse therapy has been advocated especially in Japan as a viable alternative. Here, we report a case of an elderly male patient with a history of metastatic stage 4 renal cell carcinoma who was treated with anti-impulse therapy for an acute type-A IMH. Blood pressure stabilization and continuous monitoring resulted in complete resolution of the IMH within 6 days. This report illustrates how immediate medical management in patients with acute type-A IMH who are not surgical candidates can alleviate the progression or even lead to regression as early as 1 week after initiating anti-impulse therapy.